Evanston-based biopharmaceutical company Aptinyx Inc. Thursday said a drug it is studying to treat patients with painful diabetic peripheral neuropathy failed a recent clinical study.The drug, NYX-2925, did not achieve statistically significant separation from a placebo on the study’s primary endpoint, which assessed the change from baseline in average daily pain on the numeric rating scale, the company said.
Related posts
-
Three-term Village President Wallace to hand reins to lifelong Bartlett resident Gunsteen
If Bartlett Village President Kevin Wallace needed evidence his three terms were successful in erasing personal... -
Proposal to raise age for senior road tests clears first legislative hurdle
The Illinois House passed legislation Wednesday changing mandatory road tests from age 79 to 87. Next... -
Illinois Senate President Don Harmon disagrees $4 million he took in political donations was improper
He disagrees with state election officials, but Senate President Don Harmon said he's taking questions about...